Cardiff Oncology Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2009
Net Income	-40.23	-41.47	-38.73	-28.32	-22.6	-16.71	Upgrade
Depreciation & Amortization	0.41	0.4	0.24	0.45	0.47	0.49	Upgrade
Share-Based Compensation	4.57	4.51	4.26	3.23	1.77	0.88	Upgrade
Other Operating Activities	5.28	5.65	0.39	1.57	0.76	1.77	Upgrade
Operating Cash Flow	-29.97	-30.89	-33.82	-23.04	-16.32	-13.27	Upgrade
Capital Expenditures	-0.65	-0.58	-1.01	-0.21	-0.21	-0.07	Upgrade
Change in Investments	34.16	36.78	39.04	-131.24	0	0	Upgrade
Other Investing Activities	-	-	0.11	-	-	-	Upgrade
Investing Cash Flow	33.5	36.2	38.15	-131.45	-0.21	-0.07	Upgrade
Share Issuance / Repurchase	0.11	0	0.08	35.45	137.32	12.12	Upgrade
Other Financing Activities	-	-	-	-	-0.01	-0.04	Upgrade
Financing Cash Flow	0.11	0	0.08	35.45	137.31	12.08	Upgrade
Net Cash Flow	3.64	5.31	4.4	-119.04	120.79	-1.26	Upgrade
Free Cash Flow	-30.62	-31.47	-34.83	-23.25	-16.53	-13.34	Upgrade
Free Cash Flow Margin	-5020.00%	-6448.57%	-9022.28%	-6474.93%	-4515.30%	-5451.09%	Upgrade
Free Cash Flow Per Share	-0.69	-0.70	-0.80	-0.60	-0.79	-2.23	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).